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The obvious question is: why?
Why should Josef Penninger
interrupt his career when it is at its
peak and return to Austria, a
country hardly known for
innovative, cutting-edge research?
And why should he choose to
come to Vienna, where as he
himself says he will be ‘moving in
to a minefield?’
The decision was far from easy.
Penninger readily admits to a
feeling of relief when in 1990 he
left Austria to take up a post-
doctoral position in Ontario. He
remains openly critical of the
Austrian university system. The
major problem he sees is that too
many people have tenured
positions, which means that there
are simply no positions available
to promising young scientists.
To have any real chance of
making a career in science,
people are being forced to leave
the country. The ongoing reform
of the Austrian university structure
will not do anything to address the
main problems. Furthermore,
there is a relatively low level of
investment in basic research in
Austria. Penninger himself feels
that ‘Austria is twenty years
behind the US’ in this respect.
Another problem relates to the
comparatively high level of
bureaucracy that must be
overcome for non-Austrians to
take up residence in the country.
Although himself an Austrian,
Penninger is forced to struggle
with this: his wife is Chinese and
their three small children are
Canadian. In contrast the US
offers foreigners the chance to
integrate into society and to
obtain permanent scientific
positions, so is able to compete
for the best scientists, irrespective
of their origin.
The career path of Austrian
scientists is surprisingly
standardised: a PhD is followed
by a brief research stay abroad
and those who are successful
return to Austria and take the
‘Habilitation’ (professorial
examinations) before embarking
on a lengthy wait for a free
position. In accordance with this,
Penninger decided in 1993/94 that
the time was right for him to
return to Austria. He had an offer
from Innsbruck, where he had
completed his PhD in the
laboratory of Georg Wick, but
somehow this ‘didn’t feel right’,
he says.
He therefore applied for a few
other positions in Europe but was
not selected for any of them: the
Institute for Molecular Pathology
(IMP) was one of several institutes
to reject his application speedily.
Penninger thus decided to remain
in Canada, where he took up a
position in the Toronto
laboratories of Amgen, a
biotechnology company with its
headquarters in California.
Simultaneously he held a teaching
position at the Department of
Immunology, University of
Toronto.
By any standards Penninger has
been remarkably successful. His
work on the molecular
mechanisms of T-cell
development and of autoimmunity
has received wide acclaim. His
discovery that the tumour
necrosis factor family member
RANKL is a key regulator of bone
metabolism has provided fresh
impetus to research on
osteoporosis. 
Penninger’s results have paved
the way for progress in the
treatment of medical conditions
that are among the most
widespread in developed
countries: osteoporosis is
associated with medical costs of
50 billion dollars per year in the
United States alone.
Penninger himself has been the
recipient of many awards. In the
year 2000 he was elected ‘Young
leader in medicine in Canada’ by
the Globe and Mail, he has twice
featured in the ‘Top 10’ of the
most current scientists of the year
and in 2001 he was included in
Canada’s ‘Top 40 under 40’. The
magazine ‘Esquire’ included him
in its list of the ‘Ten most
interesting people of the year
2000’, which represents an
extraordinary accomplishment for
a scientific researcher. Esquire
magazine also included Penninger
in its December 2002 ‘The best
and Brightest’ issue, which
featured 40 people from such
wide-ranging fields as
architecture, culture, politics and
science.
Research in a profit-motivated
company has provided Penninger
with many opportunities and he
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feels it has taught him a lot.
Academics are frequently
reluctant to question why
particular lines of research should
be followed and can be guilty of
setting only imprecise timetables.
Companies are far more focussed
on efficiency, an approach
sometimes lacking in academic
circles.
Nevertheless, Penninger is
concerned at the effects on
research of the American laws
governing gene patenting. It
seems as though ‘everything we
do belongs to a company, every
thought we have,’ he says.
Penninger drew the inevitable
conclusion and decided that he
should return to academia.
The offer to lead the IMBA thus
came at the right time and
despite many other options
Penninger accepted it. His
decision was only taken after
much deliberation and no single
factor can account for it. Part of
the reason stems from the
success of the IMP, a private
institution in Vienna performing
basic research under the
directorship of Kim Nasmyth. ‘The
IMP is brilliant, world-class,’  he
says.  As a result, Vienna is now
well and truly on the scientific
map. Penninger believes that he
will be able to carry out important
research in collaboration with
scientists at the IMP. He also
hopes to work together with other
institutions, such as those at the
neighbouring Biocentre, and with
research departments housed in
hospitals like the St Anna
Kinderspital (Children’s Hospital).
The present level of interactions
between the different research
institutions in Vienna is not
especially high and Penninger
hopes to contribute to an
improvement.
Penninger’s interactions with
people are characterised by
respect. He believes firmly that, ‘if
we do good science people will
respect us’. He is aware that many
people are jealous of his success
and he sees this as part of a larger
problem in science. He recognises
that jealousy can be hard to avoid:
the people with the best
publications are invited to the
best meetings and thus form the
best international connections,
thereby helping them produce
further good publications. Science
is ultra-competitive and a small
difference in perceived success
can lead to a major discrepancy in
funding and/or career
possibilities. Nevertheless,
Penninger is adamant that
jealousy has no place in science
whatsoever. ‘Science can only
succeed when we work in a spirit
of open collaboration and not
ruthless competitiveness. In all my
experience, collaboration was
always by far the better choice
and invariably worked well for
both sides,’ he says. `The
scientific community should really
get together to make science fun
again,’  he says. 
Despite his success, Penninger
is conscious of the need to keep
producing work of the highest
quality. As he says, ‘You are only
as good as your latest paper.’ The
IMBA will be concentrating on
topics that are attracting the
attention of some of the largest
and most influential groups in the
world. It is hoped that the institute
will succeed by applying original
approaches to the questions it
studies and by being quick to
identify interesting issues. In
Penninger’s view, ‘Science is like
a big desert with very few water-
holes. The trick is to find the next
oasis before everybody else
does.’
Penninger has strong views on
the position of women in scientific
research. He is aware that many
women tend to abandon scientific
careers and feels that this
represents a huge loss of brilliant
people. The reasons for their
decisions to drop out of research
need to be addressed.
Penninger has had many female
students in his group, none of
which has dropped out.
Furthermore, they have been just
as successful as the male
students he has supervised.
Penninger insists that the IMBA
will hire the best people it can,
irrespective of their gender.
He sees no reason why it is not
possible to combine science with
family life. He himself now works
from about 9:00 to 6:00 and has
not worked at weekends for over
five years. He feels that limiting
his time in the laboratory enables
him to be more focussed while at
the same time preventing him
from becoming ‘indoctrinated by
science and just as important, you
need some distance to avoid
becoming too frustrated when
things are not going well,’ he says.
Penninger’s hope is that it will
be possible to establish a US-
style research centre in Vienna.
This will only be possible if the
institute is organised on
fundamentally different principles
from those used in other Austrian
research institutes. In this respect
the IMBA represents a genuine
experiment: it is the first institute
of the Austrian Academy of
Sciences where the staff are not
offered permanent positions.
Penninger hopes that it will be a
model for other institutions in the
future.
The IMBA will be run in the
belief that providing young
scientists with the best possible
support will enable them to
develop to their full potential and
thus to have the maximum chance
of establishing themselves in a
competitive environment.
Penninger sees part of his duty as
‘protecting young investigators
from nonsense politics and
encouraging them to follow wild
ideas, even if the results can only
be published in ten years.’
Talking to Penninger, one is
immediately struck by his
optimism. He is taking up his new
position in the firm belief that he
will be successful and that both
he and Austrian science as a
whole will benefit. His is aware of
the difficulties associated with his
task, he knows that his critics
question his lack of experience in
administration and he is all too
aware that many are hoping he
will fail.
Despite all the potential
difficulties he feels that, ‘You need
to be able to look beyond the
politics. It is important to do good
science that makes a difference.
The time is now right to try.’ His
belief that he will be able to make
a difference to science in Austria,
perhaps an even greater
difference than he has already
made to science in Canada, is
possibly the largest single factor
behind his decision to return to
his native country.
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